Endoscope + Radiofrequency Ablation (Rfa) Market Overview:

The global endoscope + radiofrequency ablation (RFA) market was valued at $3,567 million in 2017 and is estimated to reach at $7,471 million by 2025, registering a CAGR of 9.6% from 2018 to 2025. Endoscope + radiofrequency ablation (RFA) is an advanced treatment modality in which endoscope devices are used in conjunction with radiofrequency ablation devices for the treatment of cardiac disorders, oncological disorders, and pain management. The potential of endoscopic RFA is being evaluated in the treatment of early esophageal squamous intra-epithelial neoplasia along with  gastric diseases, rectal diseases, and biliary diseases.

Get more information on this report : Request Sample Pages

The key factors that boost the growth of the global endoscope + radiofrequency ablation (RFA) market include upsurge in demand for novel treatment methods for patients suffering from cancer, cardiovascular diseases, and disorders associated with chronic pain along with the benefits offered by this advanced treatment modality. Several research studies have concluded that radiofrequency ablation (RFA) treatment efficiently creates lesion in the targeted body parts while maintaining short procedure durations. However, complications associated with the endoscope + radiofrequency ablation (RFA) procedure and the limited awareness regarding available endoscopic RFA devices are expected to hamper the market growth. Conversely, emerging indications for the endoscopic radiofrequency ablation offer profitable opportunities for the expansion of the market.

Get more information on this report : Request Sample Pages

Application segment review

Based on application, the endoscope + radiofrequency ablation (RFA) market is classified into four segments—oncology application, pain management, cardiology application, and other applications. The cardiology application segment registered the highest revenue in 2017 and is expected to maintain this trend throughout the forecast period. The dominant position of this segment in the global market is majorly contributed by the increase in the patient pool suffering from arrhythmia. Whereas, the oncology application segment is expected to record the highest CAGR from 2018 to 2025. Radiofrequency ablation (RFA) is a safe, minimally invasive, and an effective modality for the destruction of tumors. In addition, RFA is largely used for the ablation of liver cancer and serves as a practical alternative in inoperable patients.

Get more information on this report : Request Sample Pages

Geography segment review

Region-wise, the endoscope + radiofrequency ablation (RFA) market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America dominated the market in 2017, accounting for the highest share, and is anticipated to maintain this trend throughout the forecast period. North America is an established market for radiofrequency device ablation technologies, wherein adoption of the newest RFA devices is at its earliest. However, the Asia-Pacific region is projected to register the highest growth rate from 2018 to 2025. China and India have undergone rapid economic progress, and the healthcare industry in these two aforementioned countries witness continuous evolution. This has led several market players to invest in the emerging countries.

The report provides a comprehensive analysis of the key players operating in the global endoscope + radiofrequency ablation (RFA) market, such as Boston Scientific Corporation Conmed Corporation, Medtronic Plc (Covidien Plc), Smith & Nephew Plc, Stryker Corporation, Halyard Health, Inc., Abbott Laboratories (St. Jude Medical, Inc.), AngioDynamics, Inc., Hologic, Inc, and AtriCure, Inc. Other prominent players in the value chain include Diros Technology, Inc., Arthrex, Inc., Biotronik, Cosman Medical, Inc., Fcare Systems, Johnson & Johnson (Biosense Webster & DePuy Mitek), Stockert GmbH, and ENDO-FLEX GmbH.

Key Benefits

• The study provides an in-depth analysis with the current trends and future estimations of the global endoscope + radiofrequency ablation (RFA) market.
• A comprehensive analysis of the factors that drive and restrict the market growth is provided.
• The quantitative analysis of the industry from 2017 to 2025 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
• An extensive analysis of key segments of the industry is provided to understand the applications of endoscope + radiofrequency ablation (RFA) used globally.
• The key players and their strategies are analyzed to understand the competitive outlook of the market.

 Key Market Segments

• By Application
  • Oncology application
  • Pain management
  • Cardiology application
  • Other application
• By Region
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

 
Key Market Players

• AngioDynamics, Inc.
• Abbott Laboratories
• Conmed Corporation
• Smith & Nephew Plc
• Halyard Health, Inc.
• Hologic, Inc.
• Boston Scientific Corporation
• Medtronic Plc
• Stryker Corporation
• AtriCure, Inc.

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments

1.3.1. List of key players profiled in the report

1.4. Research methodology

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. Key findings of the study
2.2. Top winning strategies

2.2.1. Top Winning Strategies, By Year, 2016-2018*
2.2.2. Top Winning Strategies, By Development, 2015-2018* (%)
2.2.3. Top Winning Strategies, By Company, 2015-2018*
2.2.4. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Endoscope + radiofrequency ablation (RFA) market: Innovative products

3.2.1. Barex 360
3.2.2. Habib EUS RFA catheter
3.2.3. Temperature-resistant probes

3.3. Clinical trials: RFA and RFA+endoscope products in pipeline
3.4. Market dynamics

3.4.1. Drivers

3.4.1.1. Increase in the prevalence of cancer and cardiac ailments across the globe
3.4.1.2. Large scale adoption of endoscopic RFA devices in pain management
3.4.1.3. High efficacy and short duration of the procedure

3.4.2. Restraints

3.4.2.1. High costs associated with the RFA treatment
3.4.2.2. Limited awareness regarding available RFA+endoscope devices

3.4.3. Opportunity

3.4.3.1. Emerging indications for the endoscopic radiofrequency ablation

CHAPTER 4: ENDOSCOPE + RADIOFREQUENCY ABLATION (RFA) MARKET, BY APPLICATION

4.1. Overview

4.1.1. Market size and forecast

4.2. Oncology application

4.2.1. Market size and forecast

4.3. Pain management

4.3.1. Market size and forecast

4.4. Cardiology application

4.4.1. Market size and forecast

4.5. Other applications

4.5.1. Market size and forecast

CHAPTER 5: ENDOSCOPE + RADIOFREQUENCY ABLATION (RFA) MARKET, BY REGION

5.1. Overview

5.1.1. Market size and forecast

5.2. North America

5.2.1. Key trends and opportunities
5.2.2. North America market size and forecast, by country

5.2.2.1. U.S. market size and forecast
5.2.2.2. Canada. market size and forecast
5.2.2.3. Mexico market size and forecast

5.2.3. North America market size and forecast, by application

5.3. Europe

5.3.1. Key trends and opportunities
5.3.2. Europe market size and forecast, by country

5.3.2.1. Germany market size and forecast
5.3.2.2. France market size and forecast
5.3.2.3. UK market size and forecast
5.3.2.4. Italy market size and forecast
5.3.2.5. Spain market size and forecast
5.3.2.6. Rest of Europe market size and forecast

5.3.3. Europe market size and forecast, by application

5.4. Asia-Pacific

5.4.1. Key trends and opportunities
5.4.2. Asia-Pacific market size and forecast, by country

5.4.2.1. Japan market size and forecast
5.4.2.2. China market size and forecast
5.4.2.3. India market size and forecast
5.4.2.4. Australia market size and forecast
5.4.2.5. South Korea market size and forecast
5.4.2.6. Rest of Asia-Pacific market size and forecast

5.4.3. Asia-Pacific market size and forecast, by application

5.5. LAMEA

5.5.1. Key trends and opportunities
5.5.2. LAMEA market size and forecast, by country

5.5.2.1. Brazil market size and forecast
5.5.2.2. Saudi Arabia market size and forecast
5.5.2.3. South Africa market size and forecast
5.5.2.4. Rest of LAMEA market size and forecast

5.5.3. LAMEA market size and forecast, by application

CHAPTER 6: COMPANY PROFILES

6.1. Boston Scientific Corporation

6.1.1. Company overview
6.1.2. Company snapshot
6.1.3. Operating business segment
6.1.4. Business performance
6.1.5. Key strategic moves and developments

6.2. Conmed Corporation

6.2.1. Company overview
6.2.2. Company snapshot
6.2.3. Operating business segment
6.2.4. Business performance
6.2.5. Key strategic moves and developments

6.3. Medtronic Plc

6.3.1. Company overview
6.3.2. Company snapshot
6.3.3. Operating business segment
6.3.4. Business performance
6.3.5. Key strategic moves and developments

6.4. Smith & Nephew Plc

6.4.1. Company overview
6.4.2. Company snapshot
6.4.3. Operating business segment
6.4.4. Business performance

6.5. Stryker Corporation

6.5.1. Company overview
6.5.2. Company snapshot
6.5.3. Operating business segments
6.5.4. Business performance
6.5.5. Key strategic moves and developments

6.6. Halyard Health, Inc.

6.6.1. Company overview
6.6.2. Company snapshot
6.6.3. Operating business segments
6.6.4. Business performance

6.7. AngioDynamics, Inc.

6.7.1. Company overview
6.7.2. Company snapshot
6.7.3. Operating business segments
6.7.4. Business performance

6.8. Hologic, Inc.

6.8.1. Company overview
6.8.2. Company snapshot
6.8.3. Operating business segments
6.8.4. Business performance
6.8.5. Key strategic moves and developments

6.9. AtriCure, Inc.

6.9.1. Company overview
6.9.2. Company snapshot
6.9.3. Operating business segments
6.9.4. Business performance

6.10. Abbott Laboratories

6.10.1. Company overview
6.10.2. Company snapshot
6.10.3. Operating business segments
6.10.4. Business performance

LIST OF TABLES

TABLE 01. CLINICAL TRIALS, RADIOFREQUENCY ABLATION DEVICES MARKET, 2013-2016
TABLE 02. GLOBAL ENDOSCOPE + RADIOFREQUENCY ABLATION (RFA) MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 03. ENDOSCOPE + RADIOFREQUENCY ABLATION (RFA) MARKET FOR ONCOLOGY APPLICATIONS, BY REGION, 2017-2025 ($MILLION)
TABLE 04. ENDOSCOPE + RADIOFREQUENCY ABLATION (RFA) MARKET FOR PAIN MANAGEMENT, BY REGION, 2017-2025 ($MILLION)
TABLE 05. ENDOSCOPE + RADIOFREQUENCY ABLATION (RFA) MARKET FOR CARDIOLOGY APPLICATIONS, BY REGION, 2017-2025 ($MILLION)
TABLE 06. ENDOSCOPE + RADIOFREQUENCY ABLATION (RFA) MARKET FOR OTHER APPLICATIONS, BY REGION, 2017-2025 ($MILLION)
TABLE 07. ENDOSCOPE + RADIOFREQUENCY ABLATION (RFA) MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 08. NORTH AMERICA ENDOSCOPE + RADIOFREQUENCY ABLATION (RFA) MARKET, BY COUNTRY, 2017-2025 ($MILLION)
TABLE 09. NORTH AMERICA ENDOSCOPE + RADIOFREQUENCY ABLATION (RFA) MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 10. EUROPE ENDOSCOPE + RADIOFREQUENCY ABLATION (RFA) MARKET, BY COUNTRY, 2017-2025 ($MILLION)
TABLE 11. EUROPE ENDOSCOPE + RADIOFREQUENCY ABLATION (RFA) MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 12. ASIA-PACIFIC ENDOSCOPE + RADIOFREQUENCY ABLATION (RFA) MARKET, BY COUNTRY, 2017-2025 ($MILLION)
TABLE 13. ASIA-PACIFIC ENDOSCOPE + RADIOFREQUENCY ABLATION (RFA) MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 14. LAMEA ENDOSCOPE + RADIOFREQUENCY ABLATION (RFA) MARKET, BY COUNTRY, 2017-2025 ($MILLION)
TABLE 15. LAMEA ENDOSCOPE + RADIOFREQUENCY ABLATION (RFA) MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 16. BOSTON: COMPANY SNAPSHOT
TABLE 17. BOSTON: OPERATING SEGMENT
TABLE 18. CONMED: COMPANY SNAPSHOT
TABLE 19. CONMED: OPERATING SEGMENT
TABLE 20. MEDTRONC: COMPANY SNAPSHOT
TABLE 21. MEDTRONIC: OPERATING SEGMENT
TABLE 22. SMITH & NEPHEW: COMPANY SNAPSHOT
TABLE 23. SMITH: OPERATING SEGMENT
TABLE 24. STRYKER: COMPANY SNAPSHOT
TABLE 25. STRYKER: OPERATING SEGMENTS
TABLE 26. HALYARD: COMPANY SNAPSHOT
TABLE 27. HALYARD: OPERATING SEGMENTS
TABLE 28. ANGIODYNAMICS: COMPANY SNAPSHOT
TABLE 29. ANGIODYNAMICS: OPERATING SEGMENTS
TABLE 30. HOLOGIC: COMPANY SNAPSHOT
TABLE 31. HOLOGIC: OPERATING SEGMENTS
TABLE 32. ATRICURE: COMPANY SNAPSHOT
TABLE 33. ATRICURE: OPERATING SEGMENTS
TABLE 34. ABBOTT: COMPANY SNAPSHOT
TABLE 35. ABBOTT: OPERATING SEGMENTS

LIST OF FIGURES

FIGURE 01. ENDOSCOPE + RADIOFREQUENCY ABLATION (RFA) MARKET SEGMENTATION
FIGURE 02. RECENT PRODUCT LAUNCHES
FIGURE 03. RESTRAINTS AND DRIVERS: GLOBAL ENDOSCOPE + RFA MARKET
FIGURE 04. GLOBAL ENDOSCOPE + RADIOFREQUENCY ABLATION (RFA) MARKET, 2017-2025 ($MILLION)
FIGURE 05. ESTIMATED NEW CANCER CASES AND DEATHS, 2017: U.S.
FIGURE 06. ENDOSCOPE + RADIOFREQUENCY ABLATION (RFA) MARKET FOR ONCOLOGY APPLICATIONS, 2017-2025 ($MILLION)
FIGURE 07. RADIOFREQUENCY ABLATION FOR CHRONIC PAIN MANAGEMENT
FIGURE 08. ENDOSCOPE + RADIOFREQUENCY ABLATION (RFA) MARKET FOR PAIN MANAGEMENT, 2017-2025 ($MILLION)
FIGURE 09. FREQUENCY OF ATRIAL FIBRILLATION AMONG PATIENTS WITH ISCHEMIC STROKE, 2013-2014
FIGURE 10. ENDOSCOPE + RADIOFREQUENCY ABLATION (RFA) MARKET FOR CARDIOLOGY APPLICATIONS, 2017-2025 ($MILLION)
FIGURE 11. ENDOSCOPE + RADIOFREQUENCY ABLATION (RFA) MARKET FOR OTHER APPLICATIONS, 2017-2025 ($MILLION)
FIGURE 12. ENDOSCOPE + RADIOFREQUENCY ABLATION (RFA) MARKET FOR U.S., 2017-2025 ($MILLION)
FIGURE 13. ENDOSCOPE + RADIOFREQUENCY ABLATION (RFA) MARKET FOR CANADA, 2017-2025 ($MILLION)
FIGURE 14. ENDOSCOPE + RADIOFREQUENCY ABLATION (RFA) MARKET FOR MEXICO, 2017-2025 ($MILLION)
FIGURE 15. ENDOSCOPE + RADIOFREQUENCY ABLATION (RFA) MARKET FOR GERMANY, 2017-2025 ($MILLION)
FIGURE 16. ENDOSCOPE + RADIOFREQUENCY ABLATION (RFA) MARKET FOR FRANCE, 2017-2025 ($MILLION)
FIGURE 17. ENDOSCOPE + RADIOFREQUENCY ABLATION (RFA) MARKET FOR UK, 2017-2025 ($MILLION)
FIGURE 18. ENDOSCOPE + RADIOFREQUENCY ABLATION (RFA) MARKET FOR ITALY, 2017-2025 ($MILLION)
FIGURE 19. ENDOSCOPE + RADIOFREQUENCY ABLATION (RFA) MARKET FOR SPAIN, 2017-2025 ($MILLION)
FIGURE 20. ENDOSCOPE + RADIOFREQUENCY ABLATION (RFA) MARKET FOR REST OF EUROPE, 2017-2025 ($MILLION)
FIGURE 21. ENDOSCOPE + RADIOFREQUENCY ABLATION (RFA) MARKET FOR JAPAN, 2017-2025 ($MILLION)
FIGURE 22. ENDOSCOPE + RADIOFREQUENCY ABLATION (RFA) MARKET FOR CHINA, 2017-2025 ($MILLION)
FIGURE 23. ENDOSCOPE + RADIOFREQUENCY ABLATION (RFA) MARKET FOR INDIA, 2017-2025 ($MILLION)
FIGURE 24. ENDOSCOPE + RADIOFREQUENCY ABLATION (RFA) MARKET FOR AUSTRALIA, 2017-2025 ($MILLION)
FIGURE 25. ENDOSCOPE + RADIOFREQUENCY ABLATION (RFA) MARKET FOR SOUTH KOREA, 2017-2025 ($MILLION)
FIGURE 26. ENDOSCOPE + RADIOFREQUENCY ABLATION (RFA) MARKET FOR REST OF ASIA-PACIFIC, 2017-2025 ($MILLION)
FIGURE 27. ENDOSCOPE + RADIOFREQUENCY ABLATION (RFA) MARKET FOR BRAZIL, 2017-2025 ($MILLION)
FIGURE 28. ENDOSCOPE + RADIOFREQUENCY ABLATION (RFA) MARKET FOR SAUDI ARABIA, 2017-2025 ($MILLION)
FIGURE 29. ENDOSCOPE + RADIOFREQUENCY ABLATION (RFA) MARKET FOR SOUTH AFRICA, 2017-2025 ($MILLION)
FIGURE 30. ENDOSCOPE + RADIOFREQUENCY ABLATION (RFA) MARKET FOR REST OF LAMEA, 2017-2025 ($MILLION)
FIGURE 31. BOSTON: NET SALES, 2015-2017($MILLION)
FIGURE 32. BOSTON: REVENUE SHARE PER SEGMENT 2017(%)
FIGURE 33. BOSTON: REVENUE SHARE BY GEOGRAPHY 2017(%)
FIGURE 34. CONMED: NET SALES, 2015-2017 ($MILLION)
FIGURE 35. CONMED: REVENUE BY SEGMENT, 2016 (%)
FIGURE 36. CONMED: NET SALES, 2015-2017 ($MILLION)
FIGURE 37. MEDTRONIC: NET SALES, 2015-2017($MILLION)
FIGURE 38. MEDTRONIC: REVENUE SHARE PER SEGMENT 2017(%)
FIGURE 39. MEDTRONIC: REVENUE SHARE BY GEOGRAPHY 2017(%)
FIGURE 40. SMITH & NEPHEW: NET SALES, 2015-2017($MILLION)
FIGURE 41. SMITH & NEPHEW: REVENUE SHARE PER SEGMENT 2017(%)
FIGURE 42. SMITH & NEPHEW: REVENUE SHARE BY GEOGRAPHY 2017(%)
FIGURE 43. STRYKER: NET SALES, 2015-2017($MILLION)
FIGURE 44. STRYKER: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 45. STRYKER: REVENUE SHARE BY GEOGRAPHY, 2017(%)
FIGURE 46. HALYARD: NET SALES, 20152016($MILLION)
FIGURE 47. HALYARD: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 48. HALYARD: REVENUE SHARE BY GEOGRAPHY, 2016(%)
FIGURE 49. ANGIODYNAMICS: NET SALES, 20152016($MILLION)
FIGURE 50. ANGIODYNAMICS: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 51. ANGIODYNAMICS: REVENUE SHARE BY GEOGRAPHY, 2016(%)
FIGURE 52. HOLOGIC: NET SALES, 20152016($MILLION)
FIGURE 53. HOLOGIC: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 54. HOLOGIC: REVENUE SHARE BY GEOGRAPHY, 2016(%)
FIGURE 55. ATRICURE: NET SALES, 2015-2017($MILLION)
FIGURE 56. ATRICURE: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 57. ATRICURE: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 58. ABBOTT: NET SALES, 2015-2017($MILLION)
FIGURE 59. ABBOTT: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 60. ABBOTT: REVENUE SHARE BY GEOGRAPHY, 2017 (%)